Business & Management
Global

Business & Management Experts

Shankari Mylvaganam, Ph.d.

Co-founder and Vice President of Research
Business
Sapient Discovery
United States of America

Biography

Dr. Mylvaganam established the Crystallography Department at Structural Bioinformatics, Inc., where she directed the protein production and X-ray-crystallography of therapeutic protein targets for drug discovery (1997-2005).  She grew the team of structural biologists and planned and successfully directed the cloning, expression, purification and crystallography of a number of novel protein targets for customer-based and in-house programs. The customers included Johnson and Johnson, Janssen Pharmaceutica, Atherogenics, Inc., AGY Therapeutics and Pierre Fabre. She played an integral role in the structure-based inhibitor design in the in-house PTP1B Diabetes program and also headed the homology modeling efforts at Cengent. Her key contribution to the Diabetes program was to determine the first and several additional co-crystal structures of Cengent inhibitors bound to PTP1B.  She has determined crystal structures of novel proteins and protein-inhibitor bound complexes of the phosphatase and kinase families. Dr. Mylvaganam determined the high-resolution crystal structures and structure-function mechanisms of the E8 antibody in both its free state and with it bound to cytochrome-c, as well as novel hemoglobin exhibiting the Root Effect.  Her research findings were published in prominent peer-reviewed journals. She has authored many scientific manuscripts in the field of crystallography and homology modeling, and, is a co-author on several PTP1B patents.  Dr. Mylvaganam worked with the School of Pharmacy, University of London, on the structural studies of inhibitor bound viral protease. Her post-doctoral studies were conducted at The Scripps Research Institute. Dr. Mylvaganam holds a Ph.D. in Protein Crystallography from Birkbeck College, University of London, England. Dr. Mylvaganam established the Crystallography Department at Structural Bioinformatics, Inc., where she directed the protein production and X-ray-crystallography of therapeutic protein targets for drug discovery (1997-2005).  She grew the team of structural biologists and planned and successfully directed the cloning, expression, purification and crystallography of a number of novel protein targets for customer-based and in-house programs. The customers included Johnson and Johnson, Janssen Pharmaceutica, Atherogenics, Inc., AGY Therapeutics and Pierre Fabre. She played an integral role in the structure-based inhibitor design in the in-house PTP1B Diabetes program and also headed the homology modeling efforts at Cengent. Her key contribution to the Diabetes program was to determine the first and several additional co-crystal structures of Cengent inhibitors bound to PTP1B.  She has determined crystal structures of novel proteins and protein-inhibitor bound complexes of the phosphatase and kinase families. Dr. Mylvaganam determined the high-resolution crystal structures and structure-function mechanisms of the E8 antibody in both its free state and with it bound to cytochrome-c, as well as novel hemoglobin exhibiting the Root Effect.  Her research findings were published in prominent peer-reviewed journals. She has authored many scientific manuscripts in the field of crystallography and homology modeling, and, is a co-author on several PTP1B patents.  Dr. Mylvaganam worked with the School of Pharmacy, University of London, on the structural studies of inhibitor bound viral protease. Her post-doctoral studies were conducted at The Scripps Research Institute. Dr. Mylvaganam holds a Ph.D. in Protein Crystallography from Birkbeck College, University of London, England.

Research Interest

Business

Global Experts from United States of America

Global Experts in Subject

Share This Profile